Print Page     Close Window     

SEC Filings

20-F
AC IMMUNE SA filed this Form 20-F on 03/21/2019
Entire Document
 

CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 24B-2
UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION.

 

Lilly Forward-Looking Statement

 

This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about the benefits of the license and collaboration with AC Immune, and reflects Lilly's current beliefs. However, as with any such undertaking, there are substantial risks and uncertainties in the process of drug development and commercialization. Among other things, there can be no guarantee that Lilly will realize the expected benefits of the license and collaboration, or that the license and collaboration will yield a commercially successful product. For a further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, please see Lilly's most recent Forms 10-K and 10-Q filed with the U.S. Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.

 

For further information, please contact:

 

AC Immune Corporate – Europe

David A. Lowe, PhD

Phone: +41 79 281 6494

E-mail: david.lowe@acimmune.com

 

AC Immune Media Relations – US

LaVoieHealthScience

Katie Gallagher

Phone: +1 617-792-3937

E-mail: kgallagher@lavoiehealthscience.com

 

AC Immune Investor Relations

Lisa Sher

Phone: +1 970 987 26 54

E-mail: lisa.sher@acimmune.com

 

Lilly Media Relations

Mark Taylor

Phone: +1 317 276 5795

E-mail: mark.taylor@lilly.com

 

Lilly Investor Relations

Kevin Hern

Phone: +1 317 277 1838

E-mail: hern_kevin_r@lilly.com

Source: AC Immune SA

 

 


© AC Immune 2015